Prognostic Staging of Extensively Pretreated Patients with Advanced HIV-1 Disease
暂无分享,去创建一个
[1] R. Haubrich. Improved Virologic Response in Three-Class Experienced Patients When an Active Boosted Protease Inhibitor is Used with Enfuvirtide (ENF) , 2005 .
[2] Christine Katlama,et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. , 2003, The New England journal of medicine.
[3] J. Montaner,et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. , 2003, The New England journal of medicine.
[4] Jonathan AC Sterne,et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies , 2002, The Lancet.
[5] C. Sabin,et al. Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals , 2001, AIDS.
[6] J. Montaner,et al. Antiretroviral therapy for previously treated patients. , 2001, The New England journal of medicine.
[7] D. Katzenstein,et al. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359. , 2000, The Journal of infectious diseases.
[8] J. Mellors,et al. 3-Year Suppression of HIV Viremia with Indinavir, Zidovudine, and Lamivudine , 2000, Annals of Internal Medicine.
[9] P. Volberding,et al. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. , 1999, The Journal of infectious diseases.
[10] D. Richman,et al. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. , 1998, JAMA.
[11] S. Hammer,et al. Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy. , 2003, The Journal of infectious diseases.